AMD – Computational Ophthalmology

Associations between recent and established ophthalmic conditions and risk of Alzheimer's disease

Marian Blazes — Tue, 15 Jan 2019 20:17:00 +0000

Alzheimer's disease affects millions of adults and is the most common type of dementia. Identifying risk factors for Alzheimer's may lead to early detection and preventive measures that are based on a better understanding of the disease processes involved. The eye provides substantial information on brain health, and may give some clues to the pathogenesis …

Continue reading "Associations between recent and established ophthalmic conditions and risk of Alzheimer's disease"

Visual acuity improvement when switching from ranibizumab to aflibercept is not sustained

Marian Blazes — Tue, 01 May 2018 19:27:00 +0000

In this large, national, multicenter study, the authors evaluated two drugs used to treat age-related macular degeneration, the leading cause of blindness in adults over 50 in the United States. The drugs, ranibizumab and aflibercept, are vascular endothelial growth factor inhibitors, and both are used to slow disease progression (and vision loss) by preventing choroidal …

Continue reading "Visual acuity improvement when switching from ranibizumab to aflibercept is not sustained"

Cost-effectiveness of age-related macular degeneration study supplements in the UK: combined trial and real-world outcomes data.

Marian Blazes — Sun, 01 Apr 2018 23:30:00 +0000

Age-related macular degeneration is a leading cause of blindness and visual impairment, and the incidence is expected to increase as the US and UK population ages. Although there are drugs available to slow the progression of this disease, they are expensive and must be administered by intravitreal injection. Studies have found that high-dose antioxidant vitamins …

Continue reading "Cost-effectiveness of age-related macular degeneration study supplements in the UK: combined trial and real-world outcomes data."

UK AMD/DR EMR REPORT IX: comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice

Marian Blazes — Sat, 06 May 2017 17:17:00 +0000

In this multicenter study in the UK, the authors analyzed the electronic medical records of patients with age-related macular degeneration and compared two different drugs, ranibizumab and aflibercept, commonly used to treat this disease. Neovascular age-related macular degeneration is characterized by choroidal neovascularisation, which is responsible for the majority of visual loss. Intravitreal injections with …

Continue reading "UK AMD/DR EMR REPORT IX: comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice"

Deep learning is effective for the classification of OCT images of normal versus Age-related Macular Degeneration

Marian Blazes — Mon, 13 Feb 2017 22:51:00 +0000

Optical coherence tomography (OCT) is the most commonly obtained imaging modality in ophthalmology and represents a dense and rich imaging dataset when combined with labels derived from the electronic medical record. In this study, the authors developed a novel deep learning approach to distinguish normal OCT images from images from patients with age-related macular degeneration. …

Continue reading "Deep learning is effective for the classification of OCT images of normal versus Age-related Macular Degeneration"

UK AMD EMR USERS GROUP REPORT V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12

Marian Blazes — Fri, 13 Feb 2015 19:43:13 +0000

Neovascular age-related macular degeneration is characterized by the growth of abnormal, choroidal blood vessels beneath the macula. When left untreated, these blood vessels can lead to severe loss of vision. Intravitreal injection of anti-vascular endothelial growth factor-A drugs is an established therapy that helps to prevent the growth of these abnormal vessels. In the United …

Continue reading "UK AMD EMR USERS GROUP REPORT V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12"